http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-057817-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| filingDate | 2006-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-057817-A1 |
| titleOfInvention | ANTAGONISTS OF THE A2A RECEIVER OF 2-HETEROARIL-PIRAZOLO- [4,3-E] -1,2,4-TRIAZOL- [1,5-C] -PIRIMIDIN ADENOSINE. PHARMACEUTICAL COMPOSITIONS |
| abstract | Its use in the treatment of diseases of the central nervous system, in particular, Parkinson's disease and extrapyramidal syndrome, pharmaceutical compositions comprising them and combinations with other agents. Claim 1: A compound having a structural formula (1) or a salt thereof acceptable for pharmaceutical use, wherein R is R1-isoxazolyl, R1-oxadiazolyl, R1-dihydrofuranyl, R1-pyrazolyl, R1-imidazolyl, R1-pyrazinyl or R1-pyrimidinyl; R1 is 1, 2 or 3 substituents independently selected from the group consisting of H, alkyl, alkoxy and halo; Z is R2-aryl or R2-heteroaryl; R2 is 1 to 5 substituents independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, -alkylene-OC (O) alkyl, alkoxyalkyl, (hydroxy) haloalkyl, (cycloalkyl) hydroxyalkyl, hydroxycycloalkyl, (halo) alkoxyalkyl, - C (O) alkyl, hydroxyalkoxy, alkoxyalkoxy, oxetanyloxy, halo, cyanoalkyl, haloalkyl, dialkylamino, R3-heteroaryl and R3-heteroarylalkyl; and R3 is 1 to 3 substituents independently selected from the group consisting of H, alkyl, alkoxyalkyl, hydroxyalkyl, dialkylamino and cycloalkylaminocarbonyl. |
| priorityDate | 2005-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.